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Effusion in Cleft Palate: protocol for a systematic
review of the literature and identification of a
core outcome set using a Delphi survey
Nicola L Harman1, Iain A Bruce2, Peter Callery3, Stephanie Tierney3, Mohammad Owaise Sharif1,
Kevin O’Brien1 and Paula R Williamson4*Abstract
Background: Cleft palate (CP) has an incidence of approximately 1 in 700. Children with CP are also susceptible to
otitis media with effusion (OME), with approximately 90% experiencing nontrivial OME. There are several
approaches to the management of OME in children with CP. The Management of Otitis Media with Effusion in
Children with Cleft Palate (MOMENT) study is a feasibility study that includes the development of a core outcome
set for use in future trials of the management of OME in children with CP.
Methods/Design: The MOMENT study will include a systematic review of the literature to identify a list of outcomes
that have previously been reported. This list of outcomes will be used in a Delphi study with cleft clinicians. The Delphi
study is anticipated to include three rounds. The first round will ask clinicians to score the outcome list and to add any
outcomes they think are relevant. The second round involves presentation of scores according to stakeholder group
and the opportunity for participants to rescore outcomes. To ensure that the opinion of parents and children are
sought, qualitative interviews will be completed with a purposive sample in parallel. In the final round of the Delphi
process, participants will be shown the distribution of scores, for each outcome, for all stakeholder groups separately as
well as a summary of the results concerning outcomes from the qualitative interviews with parents. A final consensus
meeting will be held with all stakeholders, including parents and children, to review outcomes.
Discussion: A core outcome set represents the minimum that should be measured in a clinical trial for a particular
condition. The MOMENT study will aim to identify a core outcome set that can be used in future trials of the
management of OME, improving the consistency of research in this clinical area.
Keywords: Core outcome set, Delphi, Consensus methods, Cleft palate, Otitis media with effusionBackground
Cleft lip and palate are among the most common congeni-
tal malformations, with an overall incidence of around 1 in
700 individuals [1]. Cleft palate (CP) results in impaired
Eustachian tube function; children with this condition are
therefore susceptible to otitis media with effusion (OME),
and approximately 90% of children with CP have a history
of nontrivial OME [1,2]. OME can impair hearing at stages* Correspondence: p.r.williamson@liv.ac.uk
4Department of Biostatistics, University of Liverpool, Shelley’s Cottage,
Brownlow Street, Liverpool L69 3GS, UK
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reproduction in any medium, provided the orthought to be important in the development of language,
behavioural and social relationships. As a consequence it
can influence the quality of life in these individuals.
There are several approaches to the management of
OME in children with CP, including watchful waiting,
the provision of hearing aids, the insertion of ventilation
tubes (grommets) or a combination of these [3]. How-
ever, treatment protocols for OME have not always been
well defined. Recently, National Institute for Clinical Ex-
cellence Guideline CG60 on the surgical management of
OME in children recommended a general care pathway
of watchful wait for 3 months followed by the insertionl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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necessary. In a systematic review directed at the early
routine insertion of ventilation tubes for management of
OME for children with CP, the authors identified 18 eli-
gible studies but only one of these was a randomised
control trial [4]. Overall the quality of the studies – de-
termined by sample size and selection, performance and
reporting bias – was low, with many being small and
without sample-size calculations.
The approach to the treatment of OME in children
with CP is further complicated by the different clinical
stakeholder groups involved in the management of these
patients and, although cleft care has been centralised in
the UK to 12 hub centres, audiological and ear nose and
throat treatment may involve visits to other hospitals
outside the cleft centre.
The Management of Otitis Media with Effusion in
Children with Cleft Palate (MOMENT) study has been
funded through a Health Technology Assessment-
commissioned call (project number 09/167) to address
the uncertainty in the treatment of OME and to address
the question ‘What is the most appropriate way to man-
age otitis media with effusion in children with cleft pal-
ate?’ by completing a feasibility study.Selection of outcomes for use in clinical trials of
treatment for OME in children with cleft palate
Clinical trials should have defined primary and second-
ary outcomes that answer questions generated by the
main hypotheses. However, when we consider outcomes
that may be used in studies of the treatment of OME in
children with CP, it appears that these are numerous and
diverse, and include outcomes such as chronic otitis
media, OME, hearing loss, Eustachian tube function, be-
haviour, receptive language and side effects of treatment,
to name a few. Furthermore, these may be influenced by
other factors associated with clefting; for example, the
effect of the palatal cleft on speech.
This diversity has been illustrated by a recent review
that aimed to identify core outcome sets (COSs) for
trials of treatment of childhood conditions. The authors
categorised outcomes measured in clinical trials for a va-
riety of paediatric conditions into six broad domains: dis-
ease activity, physical consequence of disease, functional
status, social outcome and quality of life, side effects of
therapy, and health resource utilisation [5]. Importantly,
in this review they did not retrieve any studies ascertaining
agreed core outcome domains and endpoints for OME.
In summary, it appears that the domains with the most
tangible benefits for the users and providers of care for
children with CP and OME are unknown, and traditionally
researchers have used diverse outcomes. This situation
could lead to the following potential problems.Heterogeneity between studies
This heterogeneity may be illustrated by considering the
findings of a recently published systematic review di-
rected at the early routine insertion of ventilation tubes
for management of OME in children with CP. In this re-
view the authors evaluated the literature up to 2006 (in-
cluding randomised controlled trials, controlled clinical
trials, case series and historical cohort studies) [4]. Eight-
een studies satisfied the inclusion criteria. When the out-
comes were evaluated, the studies were shown to have
used varied primary outcome measures including: hearing
loss; tympanosclerosis; parental satisfaction with treat-
ment; speech and language; and OME. Furthermore, there
was inconsistency in the method of assessment for some
outcomes in particular speech and language, which was
assessed by undefined speech and language therapist
assessment, a study-specific scale or using the Reynell De-
velopmental Language Score. This limited consistency
between studies, leading to marked heterogeneity, may re-
sult in difficult interpretation and comparison of findings
and may hinder potential meta-analysis [5,6].
Outcome reporting bias
Another relevant factor is outcome reporting bias. This bias
occurs when only a selection of results for measured out-
comes is reported in a study. For example, a tendency to re-
port only significant or positive findings results in a biased
representation of the results of a trial. There is overwhelm-
ing empirical evidence that this phenomenon occurs [7].
Core outcome sets
One strategy that has been suggested to overcome these
issues is the development of a COS, which should be
measured and reported in all randomised control trials
of a specific condition [5,6,8-11]. As a result, the risk of
outcome reporting bias and heterogeneity is reduced
and the potential for carrying out a meta-analysis for key
outcomes is increased.
The outcome measures that could potentially be used
to evaluate OME treatment are numerous and diverse,
and may also be affected by specific factors in clefting.
There is currently no COS available for clinical trials of
the management of OME in children with CP.
Aims and objectives
Aim
The aim of this study is to contribute to the develop-
ment of a COS, relevant to the surgical treatment of
OME suitable for use in studies in children with CP.
Objectives
The specific study objectives are: to identify a list of out-
comes previously reported in studies of the treatment
of OME from a systematic review of the literature; to
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prioritise outcomes from the perspective of patients who
can express their views; to compare clinician important
outcomes and patient/parent important outcomes; and
to integrate patient/parent and clinician outcomes into a
combined COS.
Methods/Design
Systematic review
The systematic review will be carried out using two
sources. We will identify outcomes reported in studies of
the early placement of ventilation tubes for children with
CP by updating the search from a previous systematic re-
view [4]. In addition, we will review outcomes measured in
studies of other surgical interventions for OME in children
with and without cleft by reviewing relevant Cochrane Re-
views. This is an efficient approach that should provide
generalisable results.
Criteria for considering studies for updating the reviews
The criteria for considering studies for updating the
Bristol review [4] and Cochrane Reviews identified
through a Cochrane Central Register of Controlled Tri-
als (CENTRAL) search are as follows.
Types of studies
Studies will include systematic reviews with/without meta-
analyses, randomised controlled trials, case controlled
trials, case series, and prospective cohorts.
Types of intervention
Any surgical intervention used to manage OME in chil-
dren with and without CP.
Types of participants
Children aged <18 years with OME.
Exclusion criteria
Nonsurgical interventions for the treatment of OME.
Search methods for identification of studies
We will use an identical search strategy to Ponduri and
colleagues [4]. This search will be applied to the CEN-
TRAL, EMBASE, MEDLINE, and the Cumulative Index
to Nursing & Allied Health Literature (CINAHL) (January
2006 to present).
For the detailed search strategies applied to each of
the databases, see Additional file 1.
Multiple databases will be utilised to maximise the sen-
sitivity of a search. CENTRAL comprises only studies that
are deemed to be controlled trials by a team of reviewers,
EMBASE, MEDLINE and CINAHL include published re-
search of various study designs. The advantages conferred
by using CENTRAL in addition to the other databases arethat trials from other sources of research (for example,
journals not indexed in MEDLINE and conference pro-
ceedings) are hand searched, and controlled trials from
these are included. This improves the chances of identify-
ing all relevant studies.
Eligibility of studies
Two review authors (MOS and KOB) will independently
assess the abstracts of studies resulting from the searches.
Full copies of all potentially relevant studies and those
appearing to meet the inclusion criteria, or for which there
were insufficient data in the title and abstract to make a
clear decision, will then be obtained.
The full-text papers will be assessed independently by
two review authors (MOS and KOB) and any disagree-
ment on the eligibility of included studies resolved through
discussion. Where resolution is not possible, a third review
author (IAB) will be consulted.
Assessment of methodological quality
The quality of describing and reporting the outcomes will
be assessed within each study by considering the following
questions:
1. Is the primary outcome clearly stated?
2. Is the primary outcome clearly defined so that
another researcher would be able to reproduce its
measurement? Where appropriate, this should
include clear description of time points, the person
measuring the outcome, how the outcome was
measured (for example, tools and methods used)
and where the outcome was measured.
3. Are the secondary outcomes clearly stated?
4. Are the secondary outcomes clearly defined?
5. Do the authors explain the use of the outcomes they
have selected?
6. Are methods used to enhance the quality of
outcome measurement (for example, repeated
measurement, training) if appropriate?
For the purpose of this study there will be no synthesis
of outcome data from the randomised control trials, and
hence a critique of the overall methodological quality of
the studies themselves is not necessary.
Data extraction
In the first instance, data will be extracted independently
and in duplicate by two review authors (NLH and IAB).
NLH and IAB will then review the extracted data together
to assess consensus and to ensure that all outcomes have
been identified. Disagreement will be resolved through
discussion; where resolution is not possible, a third review
author (PRW/KOB) will be consulted. In addition, we will
Table 1 Purposive sampling matrix of parents and
children
Child age
(years)
Treatment Total
Ventilation
tubes
Hearing
aids
Ventilation
tubes and
hearing aids
Watchful
waiting
Parent sampling matrix
0 to 5 3 3 2 2 10
6 to 8 3 3 2 2 10
9 to 11 3 3 2 2 10
Total 9 9 6 6 30
Child sampling matrix
6 to 8 3 3 2 2 10
9 to 11 3 3 2 2 10
Total 6 6 4 4 20
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clear data.
The following data will be extracted from each study:
study type; author details; year and journal of publication;
intervention(s) under investigation; whether the study
population was exclusively paediatric and CP or mixed
(children and adults, with or without CP); age and number
of children included in the study population; and inclusion
and exclusion criteria.
Outcomes
The MOMENT study outcomes will include: the outcomes
that were measured, including the method of measure-
ment; the time points at which they were measured; if
stated, the designated primary outcome; and the desig-
nated secondary outcome(s).
Data analysis and presentation
For analysis purposes, the data will be initially tabulated
so that each study is listed, and the outcomes measured
in the trial are displayed.
Outcomes will be grouped under appropriate outcome
domains. The outcome domains will be determined fol-
lowing a review of the extracted outcomes by the authors
(IAB and NLH). The outcome domains and included out-
comes will be reviewed by the Study Advisory Group to
assess suitability of the domain name and grouping of
outcomes.
Within each domain we will be able to evaluate both
how many different outcomes have been used to reflect
that domain and the frequency of selection for each in-
dividual outcome, and the times at which they were
measured will be documented.
Identification of outcomes of importance to parents and
patients
The opinions of parents and children on the treatment
of OME for children with CP are important because it is
this group who will experience the benefits and adverse
effects of treatments and they should have opportunities
to contribute to identification of the most appropriate
outcomes. The identification of outcome domains im-
portant to children and parents will be grounded in their
own accounts of what matters to them about OME and
its treatment, in keeping with the principle of privileging
the lay perspective [12].
A purposive sample of children aged 0 to 11 years with
nonsyndromic CP and experience of either surgery for
insertion of ventilation tubes or conservative manage-
ment with hearing aids will be identified from two cleft lip
and palate centres. Parents or carers, and, where able and
willing, children aged at least 6 years will be interviewed.
Qualitative sample sizes are estimated pragmatically in
order to achieve the objective of saturation. Saturationmeans that the widest range of views is represented in the
data. A sample of 30 is estimated on the basis of past ex-
perience to be sufficient for saturation, but the sample size
will be increased as resources allow if new opinions are
continuing to emerge in the final interviews.
The purposive approach to sampling will be used to
include a diversity of age group, gender and treatment
types. The aim will be to recruit in accordance with the
purposive sampling matrix (Table 1). However, the final
composition of the sample will depend on treatment prac-
tices in each age group. We will seek to maximise the rep-
resentation of ethnic and demographic diversity of the
populations in the recruitment centres in the sample.
Participants will be identified by cleft teams at partici-
pant centres to ensure that they are eligible for participa-
tion. Eligibility is based on a history of OME, an absence
of a known syndrome and the ability to complete the
interview in English.
The qualitative interviews will take the form of conver-
sations in which parents tell the stories of their child’s
cleft, OME and its treatment, and the consequences for
the child and their families. This open-ended approach
will enable parents to raise issues of most importance to
themselves and the interviewer to explore parents’ un-
derstanding of alternative treatments. A topic guide will
be used to ensure that all interviews address a set of core
issues, including important outcomes of treatment. In-
terviews will also be completed with children aged at
least 6 years and interviews adapted to meet their devel-
opmental needs. Children who have lived with cleft and
OME may have views about the way their condition is
treated and should be consulted because it is they who have
the most direct experience treatment outcomes. Visual
techniques will be employed, including drawing pictures
and using interactive screen tablet computer applications.
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cordings of consultations will be imported into qualita-
tive analysis software and analysed using the five stages
of the framework approach: familiarisation with the data
(becoming immersed in material collected); development
of a thematic framework (identifying key issues in the
transcripts); indexing data (labelling key issues that
emerge across cases); devising a series of thematic charts
(allowing the full pattern across cases to be explored and
reviewed); and mapping and interpreting data (looking
for associations, providing explanations, highlighting key
characteristics and ideas) [13]. This will provide a sum-
mary of participants’ key points about what they con-
sider important and their priorities. Interview data that
take the form of narrative explanations of the effect of
OME and treatments on participants’ lives will be
interpreted by the process of constant comparison [14]
to identify outcome domains and to understand their
importance to children and parents and their rationale
for their priorities. These outcome domains will be iden-
tified independently to the outcomes identified from sys-
tematic review of the literature.
Ethical approval for the qualitative interviews with par-
ents and children has been sought and granted by the
National Research Ethics Service – NRES North East
Committee – Greater Manchester East (reference 11/
NW/0586).
Identification of outcomes of importance to clinicians
Overview
To investigate outcomes of importance to clinicians, a
Delphi approach has been adopted so that the anonym-
ous opinions of the clinicians can be obtained in a way
that gives equal influence to all who participate, and
avoids an individual participant being overtly influenced
by the opinions of any other participant [15,16]. An over-
view of the Delphi exercise is given in Additional file 2.
Identification of potential outcomes
An initial list of potential outcomes for use in the Delphi
exercise will be obtained from the systematic review de-
scribed above. To aid interpretation of the outcomes by
clinicians and to improve the ease of use of the Delphi
system, all outcomes will be listed individually but also
grouped under a relevant domain.
Following initial review of the outcome list by the MO-
MENT Study Management Group Clinician (IAB), the list
will be circulated to the MOMENT Study Advisory Group
(SAG).The SAG is comprised of cleft clinicians representing
speech and language therapists, cleft surgeons, ear nose and
throat surgeons, audiologists and clinical psychologists.
Members of the SAG will be asked to review outcomes
relevant to their clinical field. The SAG will be asked to
review the list of outcomes for comprehension and willalso be asked to comment on the suitability of the over-
all domain under which outcomes are grouped.
The members of the study advisory group will also be
asked to participate in their own round 1 of the Delphi
exercise and to list any additional outcomes that they
think should be included. Additional outcomes identified
by the SAG will be coded and added to the list of out-
comes used in the first round of the Delphi exercise that
is sent to all clinicians. This review process will produce
a final list of outcomes identified from both the system-
atic review and additional outcomes suggested by the
SAG. Owing to their involvement in the study design
and contribution to the Delphi exercise as an expert
panel, discussions between stakeholder groups within
the SAG may influence the scoring of outcomes. For this
reason, members of the SAG will not be invited to par-
ticipate in the Delphi exercise. Instead, members of the
SAG will be invited to participate in the final consensus
meeting and to chair relevant stakeholder sessions if
appropriate.
Outcomes identified as patient-reported outcome mea-
sures or other validated tools will be reviewed and the do-
mains used within the tool used as an outcome instead of
the tool itself. Where there is uncertainty about how to
present these outcomes, the advice of two relevant clini-
cians who are members of the SAG will be sought.
Outcomes identified from the systematic review that are
related to resource use will not be included in the out-
comes list used in the Delphi exercise. Information on re-
source use that is needed for a future trial will be identified
using modelling and value of information analysis.Participants
The Delphi study will be conducted with the clinical teams
from all UK cleft centres. Clinicians will be selected only
from UK centres due to time and cost constraints. Key
clinicians are audiologists, ear nose and throat surgeons,
speech and language therapists and specialist nurses.
Other clinicians – for example, paediatricians, clinical psy-
chologists, clinical geneticists and cleft surgeons – will be
identified after consultation with the clinical director or
cleft service coordinator at each cleft centre. Clinicians will
only be invited to participate if they are involved in the
clinical care of OME in children with CP.
Identified clinical leads will be approached by email and
asked to provide contact details for all clinicians who are
part of the cleft team at their centre. Individual partici-
pants will then be emailed directly and asked to complete
an online Delphi questionnaire via an embedded link.
The number of participants invited to participate will
be documented and recruitment to round 1 assessed.
The number of participants completing subsequent rounds
will also be documented and attrition assessed.
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reminded of the importance of completing the entire
Delphi process. Reminder emails will also be sent to aid
completion of each round. Participants who agree to
take part will be asked to register and a unique identifier
will be allocated to enable tracking of attrition at each
round. Upon registration, participants will be asked to
specify their clinical role to allow identification of stake-
holder groups. All data will be stored against the unique
identifier only; participants will not be able to identify
other participants or individual responses.
All members of cleft teams will be eligible to partici-
pate and do not need to have had prior involvement in
clinical trials. Although all team members identified will
be invited to participate, it is expected that some clinical
roles will not complete the survey due to a lack of ex-
pertise in the treatment of OME. These roles may in-
clude orthodontists and paediatric dentists. Specification
of clinical role as part of the registration process will
identify minority clinical groups and the presentation of
results in round 2 determined following an analysis of
the numbers of participants in each stakeholder group.
The National Research Ethics Committee has been
consulted and confirmed that the Delphi survey with cli-
nicians does not require ethical approval.
Delphi survey
Delphi round 1
In the first round the online questionnaire will request the
participant’s name and email address together with their
cleft centre. This information will be stored in a separate
database and used to provide the respondent with a unique
identifier. A unique identifier will allow identification of
individuals completing all rounds of the Delphi exercise.
Each respondent will be asked to identify their clinical
role (that is, audiologist, speech therapist, and so forth) in
the first survey question. Participants will also be asked
for their experience in clinical research.
Participants will be asked to complete each round of the
Delphi exercise within 3 weeks of receipt of the email and
will be reminded of this at the start of each survey. A re-
minder email will be sent at the end of week 2 to prompt
completion of the survey.
Round 1 survey format
The survey will be presented in an online format (see
Additional files 3 and 4).
Round 1 content includes: the respondent’s clinical role;
a list of outcomes to be scored, ordered alphabetically;
and an option for a participant to add any additional out-
comes and to provide a score for each outcome added.
At the beginning of the survey, participants will be
presented with the information detailed in Additional file 3.
They will be asked the key question: ‘What outcomesinfluence your management of children with cleft palate,
with, or at high risk of, otitis media with effusion (OME)?’
Participants will be asked to score each of the outcomes
listed using the Grading of Recommendations, Assess-
ment, Development and Evaluations scale of 1 to 9. In the
Delphi exercise the scale will be presented in the format
1 to 9, with 1to 3 labelled ‘not important’, 4 to 6 labelled
‘important but not critical’ and 7 to 9 labelled ‘critical’
[17]. Participants will be provided with an option to add
additional outcomes that they think are relevant together
with a score for each outcome added.
Outcomes will be listed alphabetically to avoid poten-
tial weighting of outcomes caused by the order in which
they are displayed.Analysis of round 1
Additional outcomes listed by participants will be
reviewed and coded by two members of the study team
(NLH and IAB) to ensure they represent new outcomes.
If there is uncertainty then the Study Management
Group will be consulted, and the SAG as appropriate.
For each outcome, the number of participants who have
scored the outcome and the distribution of scores (as
percentage who have scored each outcome) will be
summarised by stakeholder group. All outcomes will be
carried forward to round 2.Response rate in round 1
The number of participants in each stakeholder group
who respond to round 1 will be assessed following round
1 closure. Results will be presented as: the total number
of registrations; a breakdown of respondents who have
completed the survey and their inclusion in the initial
email invitation; the total number of respondents who
completed the round; the total number of respondents
in each stakeholder group; the percentage of respon-
dents compared with potential respondents as identified
from the information provided by clinical leads; and the
percentage of respondents from other sources (not in-
cluded in original email invitation).
Continuation to round 2 will be considered based on
the response to round 1. If a low number of responders
(<10) is observed for one or more stakeholder groups,
the Delphi protocol for future rounds will be reviewed
and revised. Where there is only one stakeholder group
with a small number of respondents (potentially due to
the sample available from clinical teams) then consider-
ation will be given to grouping with another stakeholder
group. This will be done in consultation with the SAG
to ensure appropriateness of grouping.
The following proposed approach assumes sufficient
numbers of stakeholders from each group respond.
Table 2 Definitions of consensus
Consensus
classification
Description Definition
Consensus in Consensus that outcome
should be included in
the core outcome set
70% or more participants
scoring as 7 to 9 AND
<15% participants scoring
as 1 to 3
Consensus out Consensus that outcome
should not be included in
the core outcomes set
70% or more participants
scoring as 1 to 3 AND <15%
of participants scoring
as 7 to 9
No consensus Uncertainty about
importance of outcome
Anything else
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Round 2 will be presented online. In round 2, each partici-
pant will be presented with the number of respondents
and distribution of scores for each outcome for their par-
ticular stakeholder group. Participants will be shown their
score from round 1, asked to consider responses from the
other members of their stakeholder group, and asked to
rescore the outcome. Participants will also be asked
whether the outcome should be included in a COS.
In round 2, participants are asked to review the score
provided in round 1 for each of the outcomes. Any
changes to scores in light of the stakeholder group or
overall response will be documented. Those who have not
taken part in round 1 and have not provided a score will
not be invited to participate in round 2.
Analysis of round 2
The total number of participants invited to take part in
round 2 will be recorded. For each outcome, the number
of participants who have scored the outcome and the
distribution of scores will be summarised by stakeholder
group. All outcomes will be carried forward to round 3.
Delphi round 3
In round 3, participants will be shown the distribution
of scores, for each outcome, for all stakeholder groups
separately as well as a summary of the results concerning
outcomes from the qualitative interviews with parents.
Participants will then be asked to rescore all outcomes
and state whether they should be included in a COS.
Round 3 will be presented online.
Analysis round 3
The total number of participants invited to take part in
round 3 will be recorded. For each outcome, the number
of participants who have scored the outcome and the
distribution of scores will be summarised together with
the number of participants who have scored the out-
come in all rounds. Results of the stakeholder group re-
sponse will be compared with the whole group response
and the percentage agreement used to determine the
structure and focus of the final consensus meeting. Each
outcome will be classified as ‘consensus in’, ‘consensus
out’ or ‘no consensus’ according to the classifications
in Table 2.
Consensus meeting
The final phase of the study will be a face-to-face consen-
sus meeting with all participants of the clinician Delphi
exercise and the qualitative study invited. Members of the
SAG will be invited to chair relevant stakeholder sessions
as appropriate.
The results from each round of the Delphi survey will
be presented. Review of the responses from cliniciansin round 3 of the Delphi exercise and interviews with
parents and children will be used to inform the structure
and content of the consensus meeting.
Prior to the consensus meeting, participants of the
qualitative interviews will also be given the opportunity
to view the responses in the clinician Delphi exercise.
The final format of the consensus meeting will be de-
termined following review of the experiences of previous
similar projects and the agreement between the total
group scores and stakeholder group scores.
Definition of consensus
The classification described in Table 2 will be used when
determining whether consensus is reached or not.
To have reached consensus that an outcome should be
in the COS requires agreement by the vast majority re-
garding the critical importance of the outcome, with
only a small minority considering it to be not important
at all. Conversely, for consensus to have been reached
that an outcome should not be in the COS requires
agreement by the vast majority regarding the lack of im-
portance of the outcome, with only a small minority
considering it to be critically important. Whilst the
choice of thresholds is inevitably somewhat subjective,
this specification of the definition of consensus upfront
should reduce the chance of consensus being defined
post hoc in such a way as to bias the results towards the
beliefs of the research team.
Statistical considerations
Sample size
There is currently no standard method for sample size cal-
culation in Delphi processes, and thus a pragmatic ap-
proach is taken. The following sample sizes are expected
to yield a meaningful statistical analysis. However, the
number of participants in the present study is limited by
the composition and number of UK cleft centres. Efforts
will be taken to maximise the response rate across centres
and stakeholder groups.
For this study, all key clinicians from all 16 UK cleft cen-
tres (which comprise 12 UK cleft services) will be invited
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stakeholder group will be reviewed after round 1. Based on
the information currently available for eight of the cleft
centres, the estimated sample sizes for all 16 centres by
clinician stakeholder group (adjusted for an anticipated 70%
response rate) are as follows: audiologist, n = 16 (adjusted
n = 11); cleft surgeon, n = 44 (adjusted n = 31); ear nose
and throat surgeon, n = 30 (adjusted n = 21); paediatrician,
n = 12 (adjusted n = 8); specialist cleft nurse, n = 52 (ad-
justed n = 36); speech and language therapist, n = 88 (ad-
justed n = 62); and psychologist, n = 24 (adjusted n = 17).
Discussion
There is currently no published COS for OME. The de-
velopment of a COS in this clinical area aims to improve
the interpretation and comparison of future studies and
to reduce the risk of outcome reporting bias and hetero-
geneity across studies. The MOMENT study will involve
multiple key stakeholder groups to ensure that a COS is
suitable and well accepted in future research.
Additional files
Additional file 1: Systematic review search strategies.
Additional file 2: Overview of Delphi process.
Additional file 3: Delphi survey formats.
Additional file 4: Online system screenshots.
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